Granzyme B vs Granzyme K — Antibody Selection Guide

Choose Granzyme B antibodies when investigating caspase-dependent apoptosis or gasdermin-mediated pyroptosis in CTL- and NK-mediated cytotoxicity; choose Granzyme K antibodies when examining complement activation by CD8+ T-cells, caspase-independent mitochondrial pathways, or protease-activated receptor signaling in tissue inflammation. Both granzymes are serine proteases secreted by cytotoxic lymphocytes, but their mechanisms of target cell killing diverge sharply after granule release.

Researchers frequently consider these two granzymes together because both mark activated cytotoxic lymphocytes and both appear in immunological synapse exocytosis, yet their downstream effector mechanisms differ fundamentally. Granzyme B operates primarily through direct caspase activation and gasdermin-E cleavage, while Granzyme K initiates T-cell-driven complement cascades and activates BID through a caspase-independent route. Understanding which pathway is relevant to your experimental model—classical caspase-mediated killing versus complement-mediated inflammation or mitochondrial disruption—determines antibody selection. The choice also depends on whether you are tracking intracellular granzyme delivery into target cells (GZMB) or extracellular complement activation and PAR signaling (GZMK).

Quick Comparison Table

When to Choose Granzyme B

Select Granzyme B antibodies when your experimental focus is on canonical CTL and NK cell-mediated cytotoxicity through apoptotic or pyroptotic pathways. Granzyme B is the most abundant granzyme in human cytotoxic lymphocytes and the primary mediator of perforin-granzyme killing. Following perforin-mediated delivery into target cells, GZMB cleaves gasdermin-E (GSDME) at Asp270, releasing the N-terminal pore-forming domain that oligomerizes in the plasma membrane to trigger pyroptosis. This pathway is particularly relevant in tumor immunology, where GSDME expression status in cancer cells determines whether CTL attack results in immunogenic pyroptotic death or quieter apoptotic death.

Granzyme B is also essential for investigating caspase-dependent apoptosis. It directly processes caspase-3 and caspase-7 (executioner caspases) as well as caspase-9 and caspase-10, bypassing upstream initiator signals. This direct caspase activation distinguishes granzyme-mediated killing from death receptor pathways and explains the rapidity of CTL killing. Researchers evaluating immune checkpoint inhibitor efficacy, CAR-T cell function, or tumor-infiltrating lymphocyte activity routinely use Granzyme B as a functional readout of cytotoxic capacity rather than merely a marker of lymphocyte presence.

Western blot detection of Granzyme B in CTL or NK cell lysates confirms cytotoxic granule loading, while immunohistochemistry on tumor sections reveals spatial distribution of cytotoxic effectors within the tumor microenvironment. The 27 kDa band is cleanly resolved from other granzymes. In flow cytometry and immunofluorescence, Granzyme B co-staining with perforin validates granule colocalization, and transfer into target cells can be tracked in conjugate assays. GZMB is relevant across transplant rejection (monitoring alloreactive CTLs), viral immunity (tracking antigen-specific CD8+ responses), and autoimmune pathology (identifying autoreactive cytotoxic cells in tissue).

When to Choose Granzyme K

Choose Granzyme K antibodies when investigating T-cell-mediated complement activation, caspase-independent mitochondrial pathways, or protease-activated receptor signaling in inflammatory contexts. GZMK has emerged as the first identified T-cell-derived initiator of the complement cascade, functioning as both a pattern recognition molecule and a serine protease. Upon secretion from CD8+ T-cells, GZMK binds heparan sulfate glycosaminoglycans on pathogen or altered self-surfaces, then cleaves complement components C2 and C4 to initiate the lectin-like pathway independently of antibodies or classical pathway components.

This complement-activating function positions Granzyme K as central to tissue inflammation in autoimmune disease, transplant rejection, and chronic inflammatory conditions where CD8+ T-cell infiltration drives pathology. Unlike Granzyme B, which must enter target cells to function, GZMK operates extracellularly in the tissue milieu. Researchers studying allograft vasculopathy, psoriasis, inflammatory bowel disease, or rheumatoid arthritis where CD8+ T-cells contribute to complement-mediated damage will find GZMK detection more informative than GZMB for mechanistic understanding.

Beyond complement, Granzyme K cleaves and activates protease-activated receptors PAR1 (F2R) and PAR2 (F2RL1) on target cells and surrounding tissue, potentially amplifying inflammatory cytokine release. It also cleaves BID, a BH3-only pro-apoptotic protein, triggering mitochondrial outer membrane permeabilization and cytochrome C release through a caspase-independent route. This pathway is slower than GZMB-mediated killing but relevant in cells resistant to caspase activation.

Western blot detection at approximately 29 kDa distinguishes the mature processed form from the 32 kDa pro-form. Immunohistochemistry on inflamed tissue sections reveals GZMK+ CD8+ T-cells in areas of complement deposition (co-stain with C3d or C5b-9). GZMK is particularly abundant in tissue-resident memory T-cells and effector memory subsets, making it a useful marker for chronic antigen-experienced populations rather than acute cytotoxic responses.

Can They Be Used Together?

Co-detection of Granzyme B and Granzyme K provides a comprehensive view of cytotoxic lymphocyte functional heterogeneity. Not all CTLs or NK cells express both granzymes equally; the relative ratio reflects differentiation state, activation history, and microenvironmental cues. GZMB is typically more abundant in acutely activated effector cells, while GZMK is enriched in tissue-resident memory and chronically stimulated populations. Dual immunofluorescence on tissue sections can map these populations spatially—GZMB-high cells near tumor margins may indicate active killing, while GZMK-high cells in stromal regions may drive complement-mediated inflammation.

On Western blot, the two proteins are easily distinguished by molecular weight: GZMB migrates at approximately 27 kDa and GZMK at 29 kDa. Running lysates from purified CD8+ T-cells or NK cells on the same gel with sequential or multiplexed detection allows quantitative comparison of granule content. Researchers can normalize to loading controls and compare GZMB/GZMK ratios across treatment conditions, disease states, or T-cell subsets sorted by surface markers.

In flow cytometry, intracellular co-staining after fixation and permeabilization reveals single-cell heterogeneity within CD8+ or CD56+ populations. A GZMB+GZMK+ double-positive subset may represent broadly cytotoxic cells, while GZMB+GZMK− cells may specialize in direct killing and GZMB−GZMK+ cells in complement-mediated inflammation. This functional dissection is particularly informative in checkpoint inhibitor studies, where reinvigoration of exhausted T-cells may preferentially restore one granzyme over the other.

Combined use also mitigates the risk of false negatives. If cytotoxic function is preserved but GZMB is downregulated (as can occur in certain viral infections or tumor microenvironments), GZMK detection ensures cytotoxic lymphocytes are not overlooked. Conversely, in models where complement pathways are blocked, GZMB provides an independent readout of cytotoxic capacity.

Cross-Reactivity Considerations

Granzyme B and Granzyme K share structural features common to the granzyme serine protease family—similar tertiary folds, conserved catalytic triads, and granule-targeting sequences—but their primary sequences diverge sufficiently that well-characterized polyclonal antibodies show minimal cross-reactivity. The aspartate-binding pocket of GZMB and the tryptase specificity pocket of GZMK create distinct epitope landscapes. Rabbit polyclonal antibodies raised against full-length or large fragments of each granzyme typically achieve specificity through the polyclonal mixture's recognition of multiple non-conserved epitopes.

Potential cross-reactivity is more likely within subfamilies: GZMB antibodies may occasionally detect Granzyme A (GZMA) if epitopes overlap in the N-terminal prodomain, and GZMK antibodies may recognize Granzyme M (GZMM), another tryptase-family member. Western blot molecular weight differences provide a first-pass specificity check—GZMA migrates at approximately 29 kDa and GZMM at 28 kDa, so unexpected bands warrant further validation by peptide competition or knockout controls.

For immunohistochemistry, the localization pattern aids interpretation: both GZMB and GZMK localize to cytoplasmic granules in resting cells, but GZMB is more uniformly distributed in CTL and NK cells, while GZMK is more prominent in CD8+ T-cells than in NK cells in some tissues. Co-staining with lineage markers (CD8, CD56) and orthogonal granzyme markers helps confirm specificity. Species cross-reactivity is predictable—human GZMB and GZMK antibodies typically recognize mouse and rat orthologs due to high sequence conservation (above 70 percent identity), but validation in each species is necessary, particularly for GZMK where functional data are more limited in rodent models.

TPB Antibody Specifications

Triple Point Biologics offers rabbit polyclonal antibodies for both Granzyme B and Granzyme K, developed and validated over three decades of proteinase and proteinase inhibitor antibody production. Both antibodies are validated for Western blot; additional application validation in progress applications in human samples, with predicted cross-reactivity to mouse and rat based on sequence homology.

The anti-Granzyme B rabbit polyclonal antibody recognizes the 27 kDa mature form of human GZMB (UniProt P10144) and detects a single clean band on Western blot in lysates from activated CTLs, NK cells, and relevant cell lines. In immunohistochemistry, it labels cytoplasmic granules in cytotoxic lymphocytes within lymphoid tissues, tumor-infiltrating lymphocyte populations, and sites of transplant rejection. The antibody is supplied as affinity-purified IgG and has been validated in paraffin-embedded and frozen sections.

The anti-Granzyme K rabbit polyclonal antibody detects human GZMK (UniProt P49863) at approximately 29 kDa on Western blot, distinguishing the mature active form from the pro-form precursor. It is suitable for detection of GZMK in CD8+ T-cell lysates, tissue homogenates, and immunohistochemical staining of inflamed tissues where CD8+ T-cell infiltration is prominent. Like the GZMB reagent, it is affinity-purified and validated across multiple sample types.

Both antibodies are produced using immunogens spanning large portions of the mature protein to maximize epitope coverage and polyclonal diversity. Lot-to-lot consistency is maintained through standardized immunization protocols and rigorous quality control, including validation against recombinant protein standards and primary cell lysates. Researchers requiring matched reagents for multiplex or sequential detection will find both antibodies compatible in terms of buffer conditions and blocking strategies. Detailed protocols for Western blot, IHC antigen retrieval, and immunofluorescence are available on each product page.

References

1. Zhou Z, He H, Wang K, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020;368(6494):eaaz7548.
2. Wensink AC, Hack CE, Bovenschen N. Granzymes regulate proinflammatory cytokine responses. J Immunol. 2015;194(2):491-497.
3. Sharma M, Merkulova Y, Raithatha S, et al. Extracellular granzyme K mediates endothelial activation through protease-activated receptor-1. FEBS J. 2016;283(9):1734-1746.
4. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48-61.